A systematic review of cessation studies for patients with inflammatory bowel disease (IBD) concluded that about 50 percent of patients who withdrew anti-TNF-α agents after combination therapy with immunomodulators maintained remission for 24 months26. Here, TNF is linked to inflammatory bowel disease.